Join
Live feed
·
PRReleasevia Quantisnow
Yumanity Therapeutics Inc. logo

Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease; Company Plans to Advance Program to Phase 2

ByQuantisnow·Wall Street's wire, on your screen.
YMTX· Yumanity Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track YMTX (Yumanity Therapeutics Inc.) and more on Quantisnow.